(IAK) iShares U.S. Insurance - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US4642887867 • Financial
IAK: Insurance, Stocks, Futures, Options, Swaps
The iShares U.S. Insurance ETF (NYSE ARCA: IAK) is designed to provide exposure to the U.S. insurance sector by tracking the performance of its underlying index, the Dow Jones U.S. Select Insurance Index. The fund primarily invests in the component securities of this index, with at least 80% of its assets dedicated to these holdings or investments that closely mimic their economic characteristics. This targeted approach ensures the fund remains aligned with the sectors performance.
While the funds core strategy revolves around tracking its index, it retains flexibility to enhance returns or manage risk. Up to 20% of its assets may be allocated to derivatives such as futures and options, cash and cash equivalents, or other securities not included in the index. These investments are selected to improve tracking accuracy or respond to market conditions, allowing the fund to adapt while staying true to its objective.
As a non-diversified fund, IAK can concentrate its holdings in a smaller number of securities, which may heighten sector-specific risks but also offers the potential for significant gains. This structure is common in sector-specific ETFs, enabling focused exposure to the insurance industrys growth prospects.
With assets under management (AUM) of $716.71 million as of October 2023, IAK is a moderately sized ETF, providing a balance between liquidity and targeted exposure. Its focus on the insurance sector includes life insurance, property and casualty, and other related financial services, making it a tool for investors seeking to capitalize on the sectors dynamics.
Looking ahead, the insurance sectors outlook will likely be shaped by interest rates and economic conditions. Rising rates can enhance insurers investment income, particularly for life insurance companies, but may also increase competition and regulatory scrutiny. Aswath Damodaran would emphasize analyzing the sectors financial health, competitive positioning, and regulatory environment to assess future prospects. While the sector faces challenges, well-positioned companies with strong balance sheets may thrive, offering opportunities for growth in a structured risk framework.
Additional Sources for IAK ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
IAK ETF Overview
Market Cap in USD | 717m |
Category | Financial |
TER | 0.40% |
IPO / Inception | 2006-05-01 |
IAK ETF Ratings
Growth 5y | 91.1% |
Fundamental | - |
Dividend | 49.8% |
Rel. Strength Industry | -1.43 |
Analysts | - |
Fair Price Momentum | 145.52 USD |
Fair Price DCF | - |
IAK Dividends
Dividend Yield 12m | 1.47% |
Yield on Cost 5y | 3.62% |
Annual Growth 5y | 6.25% |
Payout Consistency | 94.1% |
IAK Growth Ratios
Growth Correlation 3m | 47.5% |
Growth Correlation 12m | 84.1% |
Growth Correlation 5y | 97.3% |
CAGR 5y | 20.77% |
CAGR/Max DD 5y | 0.69 |
Sharpe Ratio 12m | 1.02 |
Alpha | 12.69 |
Beta | 0.48 |
Volatility | 20.49% |
Current Volume | 30.3k |
Average Volume 20d | 48.6k |
As of March 09, 2025, the stock is trading at USD 134.32 with a total of 30,347 shares traded.
Over the past week, the price has changed by -1.26%, over one month by +3.79%, over three months by +3.10% and over the past year by +21.28%.
Yes. Based on ValueRay Analyses, iShares U.S. Insurance (NYSE ARCA:IAK) is currently (March 2025) a good stock to buy. It has a ValueRay Growth Rating of 91.07 and therefor a clear technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IAK as of March 2025 is 145.52. This means that IAK is currently overvalued and has a potential downside of 8.34%.
iShares U.S. Insurance has no consensus analysts rating.
According to ValueRays Forecast Model, IAK iShares U.S. Insurance will be worth about 162.7 in March 2026. The stock is currently trading at 134.32. This means that the stock has a potential upside of +21.11%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 162.7 | 21.1% |